Log in to your Inderes Free account to see all free content on this page.
PILA PHARMA
1.32 SEK
-9.22 %
Less than 1K followers
PILA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
-9.22 %
-35.92 %
-40.00 %
-40.67 %
-60.18 %
-61.56 %
-46.09 %
-
-83.10 %
PILA PHARMA is a clinical stage biotechnology company based in Malmö, Sweden. The company is developing novel oral therapeutics for globally common metabolic diseases such as Diabetes, Obesity and Cardiovascular diseases as well as therapeutics for Pain treatment. The company has obtained an orphan drug designation in the United States for the painful rare disease Erythromelalgia. The company is specializing in development of pharmaceutical drugs based on TRPV1-antagonists.
Read moreMarket cap
55.55M SEK
Turnover
1.36M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26.2.
2026
Annual report '25
22.4.
2026
General meeting '26
27.8.
2026
Interim report Q2'26
All
Webcasts
Press releases
ShowingAll content types
PILA PHARMA: INVITATION TO LIVE Q&A TODAY, JANUARY 27, REGARDING PRECLINICAL STUDIES AND UPCOMING CLINICAL STUDIES
BioStock: Pila Pharma prepares for clinical obesity trial despite inconclusive preclinical data
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio